SILVERARC CAPITAL MANAGEMENT, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001816307

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q1 2026 · 68 positions · Total reported value $805.05M · Top-10 concentration 50.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 15 new · 20 cut · 18 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.8% · vs SPY -10.9% · Prev Value $855.33M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.7% · vs SPY -6.9% · Latest Value $784.53M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q1 2026 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC disclosed 68 equity positions with a combined reported value of $805.05M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 50.1% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2026 were KALV ($57.90M), DNTH ($54.95M), COGT ($50.58M). By sector, the heaviest allocations are Health Care 84.5%, Financials 1.5%. Versus the prior quarter, allocation shifted toward Other (+6.0pp), Financials (+1.5pp) and away from Health Care (-7.5pp).

Versus the prior quarter, SILVERARC CAPITAL MANAGEMENT, LLC opened 15 new positions, trimmed 20 and fully exited 18, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 55% of names.

The largest new positions opened in Q1 2026 were ZBIO ($22.21M), SRRK ($16.70M), ALKS ($16.28M).

Of the 18 positions fully exited versus the prior quarter, the largest were VRDN ($10.85M), PFE ($10.44M), AVTX ($9.52M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2026)

  • ZBIO ZENAS BIOPHARMA INC · $22.21M
  • SRRK SCHOLAR ROCK HLDG CORP · $16.70M
  • ALKS ALKERMES PLC · $16.28M
  • IRON DISC MEDICINE INC · $12.53M
  • HLXC HELIX ACQUISITION CORP III · $12.28M
  • XENE XENON PHARMACEUTICALS INC · $11.50M
  • IMVT IMMUNOVANT INC · $10.29M
  • SVRA SAVARA INC · $7.81M

Fully Exited (vs previous quarter)

  • VRDN VIRIDIAN THERAPEUTICS INC · prev qtr: $10.85M
  • PFE PFIZER INC · prev qtr: $10.44M
  • AVTX AVALO THERAPEUTICS INC · prev qtr: $9.52M
  • GOSS GOSSAMER BIO INC · prev qtr: $6.62M
  • LXEO LEXEO THERAPEUTICS INC · prev qtr: $6.13M
  • AMLX AMYLYX PHARMACEUTICALS INC · prev qtr: $6.12M
  • SLNO SOLENO THERAPEUTICS INC · prev qtr: $5.44M
  • OLMA OLEMA PHARMACEUTICALS INC · prev qtr: $5.16M

Insider Transactions (Form 4)

Latest SILVERARC CAPITAL MANAGEMENT, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Silverarc Capital Management is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 67 US equity positions with a combined value of $855.33M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-116845 (status: Approved), registered 2019-06-21
  • Regulatory AUM (Form ADV): $1.61B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds
  • Website: silverarccapital.com

Portfolio Structure

  • 67 positions · $855.33M reported value (Q2 2026)
  • Top 10 holdings = 47.1% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 6.4%
  • Average position size: $12.77M

Sector Tilt

  • Health Care 98.1%
  • Financials 1.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 19 new, 16 added, 28 reduced, 20 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 84.5%
Financials 1.5%
Other 14.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.88M $57.90M 7.19%
7.19%
Add
2 654.75K $54.95M 6.83%
6.83%
Reduce
3 1.31M $50.58M 6.28%
6.28%
Add
4 1.85M $40.47M 5.03%
5.03%
Add
5 991.93K $37.81M 4.70%
4.70%
Reduce
6 354.91K $36.36M 4.52%
4.52%
Add
7 302.53K $33.69M 4.18%
4.18%
Reduce
8 2.00M $32.93M 4.09%
4.09%
Add
9 1.85M $29.96M 3.72%
3.72%
Add
10 124.66K $28.51M 3.54%
3.54%
Add
11 1.50M $27.02M 3.36%
3.36%
Reduce
12 306.00K $26.61M 3.31%
3.31%
Add
13 71.55K $23.05M 2.86%
2.86%
Reduce
14 1.14M $22.21M 2.76%
2.76%
New
15 466.35K $18.52M 2.30%
2.30%
Add
16 339.61K $16.70M 2.07%
2.07%
New
17 460.31K $16.28M 2.02%
2.02%
New
18 1.10M $13.94M 1.73%
1.73%
Reduce
19 196.03K $12.53M 1.56%
1.56%
New
20 1.21M $12.28M 1.53%
1.53%
New
21 197.76K $11.50M 1.43%
1.43%
New
22 166.35K $11.26M 1.40%
1.40%
Reduce
23 414.24K $10.29M 1.28%
1.28%
New
24 186.62K $9.41M 1.17%
1.17%
Reduce
25 50.97K $9.34M 1.16%
1.16%
Reduce
26 98.51K $9.10M 1.13%
1.13%
Add
27 144.98K $8.42M 1.05%
1.05%
Reduce
28 500.00K $8.18M 1.01%
1.01%
Add
29 1.43M $7.81M 0.97%
0.97%
New
30 717.73K $7.64M 0.95%
0.95%
Reduce
31 320.00K $7.48M 0.93%
0.93%
Reduce
32 150.91K $7.40M 0.92%
0.92%
New
33 3.32M $7.06M 0.88%
0.88%
Reduce
34 54.50K $6.22M 0.77%
0.77%
Reduce
35 511.13K $6.10M 0.76%
0.76%
Reduce
36 35.85K $5.86M 0.73%
0.73%
Reduce
37 179.70K $5.79M 0.72%
0.72%
Reduce
38 3.18M $5.78M 0.72%
0.72%
Add
39 178.38K $5.66M 0.70%
0.70%
Reduce
40 1.91M $5.03M 0.62%
0.62%
Reduce
41 71.20K $4.69M 0.58%
0.58%
New
42 684.91K $4.69M 0.58%
0.58%
New
43 144.25K $4.20M 0.52%
0.52%
Reduce
44 301.73K $3.94M 0.49%
0.49%
Reduce
45 560.65K $3.34M 0.41%
0.41%
New
46 391.90K $3.01M 0.37%
0.37%
Hold
47 648.94K $2.91M 0.36%
0.36%
Add
48 653.59K $2.88M 0.36%
0.36%
New
49 496.46K $2.75M 0.34%
0.34%
New
50 2.50M $2.62M 0.33%
0.33%
Reduce

FAQ

What did SILVERARC CAPITAL MANAGEMENT, LLC buy in 2026-Q1?

In its 2026-Q1 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC reported 68 equity positions worth $805.05M in aggregate; its largest disclosed positions were KALV ($57.90M), DNTH ($54.95M), COGT ($50.58M).

How large is SILVERARC CAPITAL MANAGEMENT, LLC's portfolio?

SILVERARC CAPITAL MANAGEMENT, LLC reported $805.05M of long equity holdings across 68 positions as of 2026-Q1. Top-10 holdings account for 50.1% of reported value.

What is SILVERARC CAPITAL MANAGEMENT, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/silverarc-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →